| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Continuing Education |
1 Division of Nuclear Medicine/PET, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; 2 Division of Cardiovascular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and 3 Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
Correspondence: For correspondence or reprints contact: Marcelo F. Di Carli, MD, Division of Nuclear Medicine/PET, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115. E-mail: mdicarli{at}partners.org
The field of nuclear cardiology is witnessing growing interest in the use of cardiac PET for the evaluation of patients with coronary artery disease (CAD). The available evidence suggests that myocardial perfusion PET provides an accurate means for diagnosing obstructive CAD, which appears superior to SPECT especially in the obese and in those undergoing pharmacologic stress. The ability to record changes in left ventricular function from rest to peak stress and to quantify myocardial perfusion (in mL/min/g of tissue) provides an added advantage over SPECT for evaluating multivessel CAD. There is growing and consistent evidence that gated myocardial perfusion PET also provides clinically useful risk stratification. Although the introduction of hybrid PET/CT technology offers the exciting possibility of assessing the extent of anatomic CAD (CT coronary angiography) and its functional consequences (ischemic burden) in the same setting, there are technical challenges in the implementation of CT-based transmission imaging for attenuation correction. Nonetheless, this integrated platform for assessing anatomy and biology offers a great potential for translating advances in molecularly targeted imaging into humans.
Key Words: myocardial perfusion imaging • PET/CT • CT angiography • cardiac PET
* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org/ce_online) THROUGH MAY 2008.
Marcelo F. Di Carli reports having an affiliation with GE Healthcare, Bracco Diagnostics, Bristol–Myers Squibb Imaging, Siemens Medical Solutions, and Astellas Pharma US, Inc. No other potential conflict of interest relevant to this article was reported.
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  L. Bockeria, O. L. Bockeria, and I. A. Goustova eComment: Re: Cardiac stunning in the clinic: the full picture Interactive CardioVascular and Thoracic Surgery, January 1, 2010; 10(1): 91 - 91. [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Klingensmith III, C. Noonan, J. H. Goldberg, D. Buchwald, J. T. Kimball, and S. M. Manson Decreased Perfusion in the Lateral Wall of the Left Ventricle in PET/CT Studies with 13N-Ammonia: Evaluation in Healthy Adults J. Nucl. Med. Technol., December 1, 2009; 37(4): 215 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rominger, T. Saam, S. Wolpers, C. C. Cyran, M. Schmidt, S. Foerster, K. Nikolaou, M. F. Reiser, P. Bartenstein, and M. Hacker 18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease J. Nucl. Med., October 1, 2009; 50(10): 1611 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salerno and G. A. Beller Noninvasive Assessment of Myocardial Perfusion Circ Cardiovasc Imaging, September 1, 2009; 2(5): 412 - 424. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dorbala, R. Hachamovitch, Z. Curillova, D. Thomas, D. Vangala, R. Y. Kwong, and M. F. Di Carli Incremental Prognostic Value of Gated Rb-82 Positron Emission Tomography Myocardial Perfusion Imaging Over Clinical Variables and Rest LVEF J. Am. Coll. Cardiol. Img., July 1, 2009; 2(7): 846 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. El Fakhri, A. Kardan, A. Sitek, S. Dorbala, N. Abi-Hatem, Y. Lahoud, A. Fischman, M. Coughlan, T. Yasuda, and M. F. Di Carli Reproducibility and Accuracy of Quantitative Myocardial Blood Flow Assessment with 82Rb PET: Comparison with 13N-Ammonia PET J. Nucl. Med., July 1, 2009; 50(7): 1062 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Beller and D. D. Watson A Welcomed New Myocardial Perfusion Imaging Agent for Positron Emission Tomography Circulation, May 5, 2009; 119(17): 2299 - 2301. [Full Text] [PDF]
|
|
|
|
 |
|
 T Chua The evolving role of molecular imaging for coronary artery disease: where do we stand today? Heart Asia, March 6, 2009; 2009(2): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Neglia and A. L'Abbate Myocardial Perfusion Reserve in Ischemic Heart Disease J. Nucl. Med., February 1, 2009; 50(2): 175 - 177. [Full Text] [PDF]
|
|
|
|
|
|
A. Holz, R. Lautamaki, T. Sasano, J. Merrill, S. G. Nekolla, A. C. Lardo, and F. M. Bengel Expanding the Versatility of Cardiac PET/CT: Feasibility of Delayed Contrast Enhancement CT for Infarct Detection in a Porcine Model J. Nucl. Med., February 1, 2009; 50(2): 259 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Slomka, L. Le Meunier, S. W. Hayes, W. Acampa, M. Oba, G. G. Haemer, D. S. Berman, and G. Germano Comparison of Myocardial Perfusion 82Rb PET Performed with CT- and Transmission CT-Based Attenuation Correction J. Nucl. Med., December 1, 2008; 49(12): 1992 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Bateman Business aspects of cardiovascular computed tomography: tackling the challenges. J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 111 - 118. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
